An Open-Label Study of Low-Level Laser Therapy Followed by Autologous Fibroblast Transplantation for Healing Grade 3 Burn Wounds in Diabetic Patients

Mohammad Ali Nilforoushzadeh1, Nooshafarin Kazemikhoo2,3*, Soheila Mokmeli4, Sona Zare1,5, Mostafa Dahmardehei6, Reza Vaghar Doost6, Mahnoush Momeni6, Fereshteh Ansari7,8

1Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, Iran
2Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Dermatology, St. George Hospital, UNSW, Sydney, Australia
4Canadian Optic and Laser Centre, COL Centre, BC, Canada
5Department of Biology, Faculty of Science, Islamic Azad University, Hamedan Branch, Hamedan, Iran
6Burn Research Centre, Department of Plastic and Reconstructive Surgery, Iran University of Medical Sciences, Tehran, Iran
7Research Centre for Evidence-Based Medicine, Health Management and Safety Promotion Research Institute, Tabriz University of Medical Sciences, Tabriz, Iran
8Iranian EBM Centre: A Joanna Briggs Institute Affiliated Group

Abstract

Introduction: Low-level laser therapy (LLLT) has been used as an effective therapeutic modality since the mid-1960s. Although there have been several clinical studies using LLLT in wound healing, especially diabetic, pressure and venous ulcers, there are few reports of using this technique in burn ulcers. Autologous fibroblast transplantation is a novel treatment for patients with burns or venous ulcers. In this study for the first time, we used LLLT along with autologous fibroblast skin transplantation to treat grade 3 burn ulcers in diabetic patients. This case series describes the successful management of grade 3 burn ulcers in 10 diabetic patients using autologous fibroblast skin transplantation along with LLLT.

Methods: After the approval of the Tehran University Ethics Committee (IR.TUMS.REC.1394.1683) and the Iran Registry of Clinical Trials (IRCT2016050226069N3), 10 diabetic patients with 10 grade 3 burn ulcers, who were a candidate for skin graft surgery, entered the study. Donor skin was biopsied using a 3 mm punch. Fibroblasts were extracted and cultured in vitro in the GMP Technique laboratory. The patients were treated using LLLT in 3-4 weeks during the time that fibroblast cultures became ready to use. Laser irradiation was done using red light, 650 nm, 150 mW, 1 J/cm² for the bed of the ulcer and infra-red light 808 nm, 200 mW, 6 J/cm² for the margins every other day for 10 sessions.

Results: The mean wound size before treatment was 16.28 cm². All patients’ burn wounds healed completely after 10-12 weeks.

Conclusion: We conclude that this method can be used as an effective method for treating large wounds, especially in complicated patients including the diabetics.

Keywords: Low-level laser therapy; Autologous fibroblast transplantation; Burn wound.

Introduction

Millions of patients are hospitalized due to burn ulcers and more than 300,000 of them die of complications. The healing process in these patients is complicated due to poor blood supply and infection. Spontaneous healing of these ulcers may cause scar formation and the patients may need surgical treatments including auto or allograft which may have limitations because of antigenicity or insufficient donor skin.

Several therapeutic modalities have been introduced for accelerating the closure time and decreasing scar formation of these ulcers, including different kinds of dressings, growth factors, and surgical methods. Autologous fibroblast or keratinocyte transplantation is one of the novel treatments for patients with burns or venous ulcers. Studies show that activated autologous fibroblasts can provide the fibroblast growth factor, the platelet-derived growth factor, and the vascular, endothelial growth factor and have a significant effect on extracellular matrix formation, differentiation, and
epidermal proliferation. A major problem is that cultivating sufficient amounts of fibroblasts requires at least 3-4 weeks and burn areas need therapeutic supports during this time.

Low-level laser therapy (LLLT) has been used as an effective, safe, and non-invasive treatment for wound healing. Low-power lasers have no thermal effects and can accelerate the healing process by stimulating microcirculation, fibroblast proliferation, granulation tissue formation, collagen synthesis, and immune system modulation. Studies show that laser therapy improves cellular metabolic processes and the regenerative capacity of injured tissues.

Our previous reports manifested the significant effects of using LLLT on the treatment of foot ulcers, burn ulcers, neuropathy, and the metabonomic of diabetic patients, increasing growth factors, the improvement of healing after cesarean surgery and coronary bypass grafting.

In this study, we evaluated two modern therapies, LLLT for phase 1 (the first 3-4 weeks that fibroblast culture lasts) and autologous fibroblast transplantation as phase 2 in patients with grade 3 burn ulcers.

**Methods**

The diabetic patients (30-68 years old) with chronic grade 3 burn ulcers (according to the University of Texas wound classification system) who were hospitalized in Shahid Motahari Burn center entered the study. They had received classic diabetic wound care including glycemic control, topical and oral antibiotic therapy for the infected wounds according to wound culture, offloading and surgical debridement, but they had no sign of improvement after 6 weeks. The patients’ primary data are shown in Table 1.

The exclusion criteria were pregnancy, photosensitivity, chronic disease that needed medication, and malignancy. After filling the questionnaire and the informed consent, standard photographs were taken of all patients using an iPhone 5 camera without flash. For obtaining fibroblast, a 3 mm punch was used for a skin biopsy from the retroauricular area after anesthesia with lidocaine 2%. The skin biopsies were placed in sterile culture media (RPMI) with 100U/ML penicillin + 100U/ML streptomycin (ATOCEL, Austria, ATRA-010) and were transferred to a clean room of the skin and stem cell research center for culturing using GMP techniques. For 3-4 weeks, LLLT was done using red light (Canadian Optic Laser Center, COL Laser, Canada), 650 nm, 150 mW, 1 J/cm² for the bed of the ulcer and infra-red light 808 nm, 200 mW, 6 J/cm² (Azor 2k Laser, Russia) for the margins every other day.

**Cell Culture**

The biopsied skins were washed with DMEM (ATOCEL, Austria ATCDH883) plus penicillin and streptomycin (ATOCEL, Austria, ATRA-010) three times, the fatty layers of the skins were removed, and the skins were cut into small pieces using a scalpel and were transferred into a 15 mL round-bottomed tube. 0.1% collagenase type 1 (ATOCEL, Austria) was added and incubated 2 hours at 37°C, Co2 5% and 95% humidity. After shaking and centrifuging at 1000 rpm for 5 minutes, sediment was added to 6 well plates and 1 mL high glucose DMEM (ATOCEL, Austria, ATCDH883), supplemented with 10% bovine serum, was added to each well. The medium was changed to a fresh one every 2 days. Upon reaching 80%-90% confluency, the cells were detached using trypsin 0.25% (ATOCEL, Austria, ATRE 10810) and sub-cultured in a 25 cm² cell flask. The plates were microscopically verified to guarantee that the cells were confluent and there was no contamination. The cultured cells were tested for mycoplasma, fungi and bacterial contamination. After 3-4 weeks, 20 million fibroblasts were isolated and suspended in 1 mL phosphate-buffered saline (PBS) for transplantation.

**Transferring Cells to the Wound Area**

We used trichloroacetic acid (TCA) 50% for chemical debridement of hyperkeratotic surrounding tissue. Then the bases of ulcers were abraded by a surgical scalpel No. 15 to create pinpoint bleeding. After washing the wound surface with normal saline, a thin layer of fibroblast suspension was applied to the base of the ulcer using a sterile sampler and its surface was covered by Vaseline gauze. The biopsied skins were washed with DMEM (ATOCEL, Austria) and cut into small pieces using a scalpel and were transferred into a 15 mL round-bottomed tube. 0.1% collagenase type 1 (ATOCEL, Austria, ATRA-010) three times, the fatty layers of the skins were removed, and the skins were cut into small pieces using a scalpel and were transferred into a 15 mL round-bottomed tube. 0.1% collagenase type 1 (ATOCEL, Austria, ATCDH883), supplemented with 10% bovine serum, was added to each well. The medium was changed to a fresh one every 2 days. Upon reaching 80%-90% confluency, the cells were detached using trypsin 0.25% (ATOCEL, Austria, ATRE 10810) and sub-cultured in a 25 cm² cell flask. The plates were microscopically verified to guarantee that the cells were confluent and there was no contamination. The cultured cells were tested for mycoplasma, fungi and bacterial contamination. After 3-4 weeks, 20 million fibroblasts were isolated and suspended in 1 mL phosphate-buffered saline (PBS) for transplantation.

**Transferring Cells to the Wound Area**

We used trichloroacetic acid (TCA) 50% for chemical debridement of hyperkeratotic surrounding tissue. Then the bases of ulcers were abraded by a surgical scalpel No. 15 to create pinpoint bleeding. After washing the wound surface with normal saline, a thin layer of fibroblast suspension was applied to the base of the ulcer using a sterile sampler and its surface was covered by Vaseline gauze and a Mepitel (Molnlycke health care, Sweden) dressing and a Tegaderm (3M, America) dressing over the Vaseline gauze to fix the cells. The Tegaderm dressing has a thin polyurethane membrane coated with acrylic adhesive. To prevent secondary infection, cephalexin 500 mg was prescribed four times a day for seven days. The dressing was removed on day seven. The patients were evaluated every other day until complete closure of the

---

**Figure 1.** (A) The burn ulcer in diabetic patients with previous amputation surgery. B: After 10 sessions of LLLT. C: Treating the ulcer with autologous fibroblast suspension. (D) The Tegaderm dressing. (E) Treatment completion.
wound. Photography was done at the end of the treatment and the pictures were analyzed using PictZar software (Figure 1). Statistical analysis was carried out using IBM SPSS version 21.

Results
Ten patients were recruited for this study. Of these patients, 7 (70%) were male and 3 (30%) were female. The mean age of them was 47 (SD: 12.96) years (range: 30 to 68 years). The mean size of burn ulcers was 16.28 cm² (SD: 8.94 cm²). The minimum size of these ulcers was 8.20 cm² and the maximum size of them was 31.03 cm². Of these ten ulcers, 2 (20%) healed completely after 10 weeks, 5 (50%) remained after 11 weeks and 3 (30%) lasted after 12 weeks from the treatment onset.

There was no linear correlation between the time to complete healing and the age of the patients (Pearson’s r = 0.511, P = 0.131) nor was there between the time to complete healing and the initial size of burn ulcers (Pearson’s r = 0.476, P = 0.165).

Discussion
In this case series for the first time, we report the effect of autologous fibroblast skin transplantation along with low-level laser irradiation in treating grade 3 burn ulcers in diabetic patients, candidates for split-thickness skin graft surgery. Complete healing occurred in all patients in at least 3 months. Our previous study showed that using LLLT after a skin graft is an effective therapeutic modality. Although the autologous skin graft is the gold standard for covering skin defects in deep burn ulcers, this method has several complications including the need to hospitalization, the risk of anesthesia and surgery, especially in patients with cardiovascular diseases, the limitation of the donor site in extensive burns, graft failure, especially in diabetic patients and donor site scars. In this study, instead of harvesting a larger area of skin as the donor site for grafting on the damaged area, we just biopsied 3 mm of the patients’ post-auricular area and culture fibroblast, along with LLLT. Our results showed complete healing in all patients in at least 3 months. Although this process is longer than using LLLT along with skin graft surgery which lasts at least 2 months, it had several advantages, including treating outpatient without need to hospitalization, avoiding surgery and its risks and independence of harvesting skin for the donor site which sometimes forms hypertrophic scars.

In our previous study, we irradiated an infra-red 810 nm laser on cultured skin fibroblasts of diabetic and non-diabetic mice. Our results showed that laser irradiation significantly increased the fibroblast growth factor gene expression in the diabetic mice. Although laser irradiation also increased the expression of the platelet-derived growth factor, it was not statistically significant.

Cell therapy has been applied in treating burn ulcers since 1975. Dermal replacement with fibroblast culture

Table 1. Characteristics of 10 Patients Included in the Study and Time to Complete the Healing of Burn Ulcers

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Duration of Ulcer (wk)</th>
<th>Area (cm²)</th>
<th>Insulin Use</th>
<th>Duration of Amputation (y)</th>
<th>Duration of History of Previous Diabetic Ulcer (y)</th>
<th>Total Ulcer Area (cm²)</th>
<th>HbA1C (mg/dL)</th>
<th>FBS (mg/dL)</th>
<th>BMI (kg/m²)</th>
<th>LDL/HDL Ratio</th>
<th>HbA1C Amputation (mg/dL)</th>
<th>Anti-biotic Use</th>
<th>Time to Healing (wk)</th>
<th>Neutrophil Use</th>
<th>Neutrophil Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>30</td>
<td>1.12</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>124</td>
<td>8</td>
<td>209</td>
<td>31.6</td>
<td>1.03</td>
<td>44.1</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>32</td>
<td>1.65</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>124</td>
<td>10</td>
<td>148</td>
<td>8.97</td>
<td>1.09</td>
<td>2.13</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>40</td>
<td>1.11</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>124</td>
<td>10</td>
<td>165</td>
<td>1.13</td>
<td>1.01</td>
<td>27.43</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>42</td>
<td>1.13</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>124</td>
<td>9</td>
<td>148</td>
<td>8.97</td>
<td>1.09</td>
<td>2.13</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>44</td>
<td>1.13</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>124</td>
<td>9</td>
<td>165</td>
<td>1.13</td>
<td>1.01</td>
<td>27.43</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>68</td>
<td>1.13</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>124</td>
<td>10</td>
<td>148</td>
<td>8.97</td>
<td>1.09</td>
<td>2.13</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>70</td>
<td>1.13</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>124</td>
<td>9</td>
<td>165</td>
<td>1.13</td>
<td>1.01</td>
<td>27.43</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>8</td>
<td>54</td>
<td>1.13</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>124</td>
<td>9</td>
<td>165</td>
<td>1.13</td>
<td>1.01</td>
<td>27.43</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>9</td>
<td>43</td>
<td>1.13</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>124</td>
<td>10</td>
<td>165</td>
<td>1.13</td>
<td>1.01</td>
<td>27.43</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>10</td>
<td>44</td>
<td>1.13</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>124</td>
<td>8</td>
<td>165</td>
<td>1.13</td>
<td>1.01</td>
<td>27.43</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>
can provide an extracellular matrix, vascularization, and granulation tissue formation and it can support the epithelial layer. Braye et al. used a widely meshed autograft with autologous cultured epithelium for treating an extensive burn in children. Wisser and Steffes reported the successful use of autologous keratinocyte and fibroblast in a burned patient. Owen et al. reported the successful use of a tissue-engineered dermal graft containing neonatal skin fibroblast for the treatment of ulcerated necrobiosis lipoidica. Nilforoushzadeh et al. reported treating a burn ulcer in diabetic patients, using autologous fibroblast suspension. They also used this technique for soft tissue augmentation and the treatment of scars and wrinkles.

Several meta-analyses and reviews suggest LLLT as an effective therapeutic modality for wound healing. Most of these clinical studies are on diabetic, venous and pressure ulcers. The effect of laser therapy on burn ulcers is studied only on animal models. Mester, the pioneer of using LLLT in wound healing, studied the effect of laser therapy on burn ulcers in mice. He concluded that laser irradiation stimulates the healing process by increasing epithelial formation.

Dantas et al. used sodium alginate/chitosan-based films along with LLLT for treating burn ulcers in mice. They reported that the combination of these two methods improves healing by modulating epithelialization, collagen formation and neovascularization. Bayat et al. reported that using laser therapy on deep second-degree burns in rats decreased the incidence of infection with Staphylococcus aureus and epidermis. Ezzati et al. showed that LLLT promoted the healing of third-degree burn ulcers in rats.

The only clinical report was our previous study on the effect of LLLT on a type 3 burn ulcer in diabetic patients after a skin graft. We concluded that LLLT is an effective therapeutic modality in burn ulcers. Gaïda et al. reported that LLLT had positive effects on patients with burn scars.

Almeida-Lopes et al. studied the effect of LLLT on the proliferation of cultured human gingival fibroblasts. They concluded that laser therapy improved the proliferation of fibroblasts in vitro.

**Conclusion**

A delay in burn wound healing increases patients’ pain and discomfort, the rate of infection, the likelihood of surgical procedures and the duration of hospitalization. Applying autologous fibroblast skin culture along with LLLT may decrease these morbidities and can be used as an effective therapeutic modality in patients with high risks for surgery or those who do not agree with skin graft surgery.

**Ethical Considerations**

The protocols and the informed consent were reviewed in the Medical Ethics Board of Tehran University of Medical Sciences (IR.TUMS.REC.1394.1683) and Iran Registry of Clinical trials (identifier: IRCT2016050226069N3; http://en.irct.ir/trial/21708).

**Conflict of Interests**

The authors declare no conflict of interest.

**Acknowledgement**

We appreciate the Canadian Laser and Optics Co. Ltd and Behsaz Laser instruments Co. Ltd for their instrumental supports and the Skin and Stem Cell Research Centre for financial support. We would also like to acknowledge Motahari Burn Center staff and our patients for their ongoing involvement.

**References**


